Retatrutide (LY-3437943) is an investigational triple agonist targeting the GLP-1, GIP, and glucagon receptors. It is in late-stage clinical trials for obesity and metabolic disease.

Is retatrutide FDA-approved?

No. Retatrutide is investigational — Phase 3 obesity trials are ongoing as of the most recent update to this entry. It is not approved by the FDA, MHRA, Health Canada, or the TGA. Research-peptide vendors sell the compound for laboratory use only.

What is the half-life of retatrutide?

Published Phase 1 pharmacokinetic data report a half-life of approximately 6 days, which is consistent with weekly dosing in the clinical trial protocols.

What dose of retatrutide is used in research?

Clinical trial protocols use graduated dose escalation over several weeks. Pepticker does not publish a dosing recommendation — refer to the published trial protocols or peer-reviewed studies for the specific schedule you are reproducing.

How does retatrutide compare to tirzepatide and semaglutide?

Retatrutide adds glucagon-receptor agonism on top of the GIP/GLP-1 activity of tirzepatide, while semaglutide is a single GLP-1 agonist. Phase 2 trial data have reported larger weight-loss effect sizes for retatrutide than for either comparator at comparable timepoints, though Phase 3 outcomes are still pending.

Is retatrutide legal?

In the US, Canada, and the UK retatrutide is sold by research-chemical vendors for laboratory use and is not approved for clinical use. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

metabolic

Retatrutide

Triple GCG/GIP/GLP-1 agonist

0 vendors tracked0 live pricesLast crawl: warming up

About

An investigational triple-agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 clinical trials for obesity are ongoing; research-compound version is sold via research-chemical vendors.

Also known as: LY-3437943, Triple agonist, RETA, Reta-3, RETA 3, RETA-3, PEP-RT, RT-3, Reta3, GLP3-R, PP-3R, Peptide 3 (R), Peptide-R, RO-3R, SA-3R, WL3-RT, rt, RT, GLP RT, GLP-3 RT, GLP3-Retatrutide, OmA – 3p, OmA – 3p 10, OmA – 3p 20, OmA – 3p 30

Reconstitution calculator

For research purposes only. Not for human consumption. Always verify calculations independently.

VialPeptide mass in vial (mg)mgBacteriostatic water added (mL)mL

DoseDesired dose

Syringe

How reconstitution works · Understanding syringe units

Cost-per-dose recalculates as you adjust the calculator above.

§ Frequently asked

Common questions about Retatrutide

What is retatrutide?: Retatrutide (LY-3437943) is an investigational triple agonist targeting the GLP-1, GIP, and glucagon receptors. It is in late-stage clinical trials for obesity and metabolic disease.
Is retatrutide FDA-approved?: No. Retatrutide is investigational — Phase 3 obesity trials are ongoing as of the most recent update to this entry. It is not approved by the FDA, MHRA, Health Canada, or the TGA. Research-peptide vendors sell the compound for laboratory use only.
What is the half-life of retatrutide?: Published Phase 1 pharmacokinetic data report a half-life of approximately 6 days, which is consistent with weekly dosing in the clinical trial protocols.
What dose of retatrutide is used in research?: Clinical trial protocols use graduated dose escalation over several weeks. Pepticker does not publish a dosing recommendation — refer to the published trial protocols or peer-reviewed studies for the specific schedule you are reproducing.
How does retatrutide compare to tirzepatide and semaglutide?: Retatrutide adds glucagon-receptor agonism on top of the GIP/GLP-1 activity of tirzepatide, while semaglutide is a single GLP-1 agonist. Phase 2 trial data have reported larger weight-loss effect sizes for retatrutide than for either comparator at comparable timepoints, though Phase 3 outcomes are still pending.
Is retatrutide legal?: In the US, Canada, and the UK retatrutide is sold by research-chemical vendors for laboratory use and is not approved for clinical use. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.

Research use only. The compounds listed on this page are not approved for human use through research-chemical channels. Nothing on this page is medical advice. Consult a qualified clinician before considering any peptide protocol. See affiliate disclosure and our scoring methodology.

Keep exploring

Common questions about Retatrutide

More on Retatrutide & related research